Blog
Clinical Connection
Thought leadership on the clinical impact on workers' compensation and auto no-fault.
2Q 2023 Brand-Generic Pipeline
The following list represents a summary of new medications approved by the U.S. Food and Drug Administration (FDA) and first-time generics or brand alternatives that potentially may be prescribed for the treatment of a workers’ compensation or auto injury. Off-label use for the treatment of conditions outside of FDA-approved indications may not be supported by medical treatment guidelines or Optum Workers’ Compensation and Auto No-Fault. Please note this list is not all-inclusive.
New medications
For more information about these medications, click on the link in the medication description to visit the manufacturer’s website.
| Medication description | Strength(s) and dosage form(s) | Class/Indication | Launch date |
|---|---|---|---|
| UzedyTM (risperidone) extended-release injectable suspension | 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 200 mg, 250 mg single-dose prefilled syringes | Atypical antipsychotic indicated for the treatment of schizophrenia | 4/28/2023 |
| Abilify Asimtufii® (aripiprazole) extended-release injectable suspension | 960 mg/3.2 ml, 720 mg/2.4 ml single-dose prefilled syringes | Atypical antipsychotic indicated for the treatment of schizophrenia in adults and for maintenance monotherapy treatment of bipolar I disorder in adults | 5/30/2023 |
If you have any questions, please contact our Clinical Services team at 1-877-275-7674 ext. 8612.
Disclaimer: The information contained herein is provided as-is for informational purposes only and does not constitute medical advice or formal utilization review. This document should not be used in place of a licensed medical practitioner’s independent medical examination, opinion or practice. Optum makes no warranties or representations as to the accuracy or effectiveness of any medical treatment guidelines, formularies or FDA-approved indications that are published after the date of this document.
